昌郁医药

Changyu Pharma is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the development of innovative therapies for pain management and central nervous system (CNS) disorders. The company utilizes its proprietary multi-target drug design platform to create novel small molecule drugs that aim to provide superior efficacy and safety compared to existing treatments. Its lead candidate, X0002, is a dual-acting analgesic currently in Phase 3 clinical trials for postoperative pain, designed to reduce opioid consumption while maintaining potent pain relief. Changyu Pharma's pipeline also includes programs for chronic pain, osteoarthritis, and neuropathic pain, leveraging a team with deep expertise in medicinal chemistry. The company is led by an experienced management team and backed by top-tier healthcare investors including Matrix Partners China and Ping An Ventures.